In November, Prof. McNally gave an update at the North American CF conference on how the RECOVER study has been progressing for the 12+ cohort, and presented some of the results seen in the first 6-month of the study. Recruitment commenced in September 2020. 116 PEOPLE WITH CF have been recruited to the study with 10 withdrawals. Ages of participants range from 12-57 years, with 55.4% male and 45.6% female. We have seen a significant and sustained reduction in sweat chloride in both homozygous and het/min patients, which compliments the clinical trial data published for Kaftrio®. We note significant increases in weight from baseline to 6-months, and significant increases in ppFEV1 from baseline to 6-months for all participants.